Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.

Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Original Publication: New York, NY : Hindawi Pub. Co.

B7-H1 Antigen*/analysis ; B7-H1 Antigen*/genetics ; B7-H1 Antigen*/metabolism ; Neoplasms, Glandular and Epithelial*/epidemiology ; Neoplasms, Glandular and Epithelial*/genetics ; Neoplasms, Glandular and Epithelial*/metabolism ; Thymus Neoplasms*/epidemiology ; Thymus Neoplasms*/genetics ; Thymus Neoplasms*/metabolism; Adult ; Aged ; Asian People/genetics ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; China/epidemiology ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged

The incidence of thymic epithelial tumors (TETs) in the Chinese population was much higher than that in the North American population. In clinical treatment, the prognosis of benign tumors after surgical resection was significantly better than that of malignant tumors. Currently, the commonly used clinical indicators for TET staging included Masaoka staging and WHO (2015) pathological criteria; however, the distinction between the benign and malignant tumors and diagnosis is yet to be explored. The current study demonstrated that the expression of PD-L1 in tumor cells was correlated with the degree of TET malignancy. The quantitative analysis of PD-L1 expression in 70 cases of TET tumor samples revealed that the positive rate of PD-L1 expression in types A, AB, B1, and B2 of thymoma (40 cases) was 37.5% (15/40), which was significantly lower than that in type B3 thymoma and thymic carcinoma (76.67%, 30 cases, 23/30) as demonstrated by chi-square test ( P < 0.05). In addition, the two methods were analyzed for the quantitative detection of PD-L1 expression. The results from the estimation of transcriptional RNA expression and quantitative protein immunohistochemistry were consistent ( r = 0.745). Furthermore, we also analyzed PD-L1 expression level in different types of TETs from TCGA database and observed that higher PD-L1 expression was in thymic carcinoma than in thymoma. Therefore, it could be concluded that PD-L1 expression in TET cells was correlated with the degree of malignancy, whereas the estimation of PD-L1 expression was potentially applicable in the clinical staging of TETs.

PLoS One. 2017 Aug 3;12 (8):e0182665. (PMID: 28771603)
Breast Cancer Res Treat. 2013 Jun;139(3):667-76. (PMID: 23756627)
Tumori. 2012 Nov;98(6):751-5. (PMID: 23389362)
Cancer Res. 2006 Apr 1;66(7):3381-5. (PMID: 16585157)
Int Immunol. 2015 Jan;27(1):39-46. (PMID: 25323844)
Lung Cancer. 2016 Sep;99:4-10. (PMID: 27565906)
Acta Histochem. 2006;108(1):19-24. (PMID: 16530813)
J Immunol. 2003 Feb 1;170(3):1257-66. (PMID: 12538684)
Lung Cancer. 2015 May;88(2):154-9. (PMID: 25799277)
Clin Cancer Res. 2007 Mar 15;13(6):1757-61. (PMID: 17363529)
Clin Cancer Res. 2016 Sep 15;22(18):4727-34. (PMID: 27166394)
Aging Cell. 2010 Oct;9(5):785-98. (PMID: 20653631)
Mod Pathol. 2017 Jun;30(6):826-833. (PMID: 28281549)
Ann Thorac Surg. 2016 Apr;101(4):1361-9. (PMID: 26794891)
Lab Invest. 2014 Jan;94(1):107-16. (PMID: 24217091)
Thorac Surg Clin. 2011 Feb;21(1):59-67, vi-vii. (PMID: 21070987)
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. (PMID: 24714771)
Hum Pathol. 2017 Feb;60:16-23. (PMID: 27746267)
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5. (PMID: 17360651)
Nat Med. 2002 Aug;8(8):793-800. (PMID: 12091876)
Lung Cancer. 2017 Feb;104:24-30. (PMID: 28212996)
Cancer Treat Rev. 2015 Dec;41(10 ):868-76. (PMID: 26589760)
J Thorac Oncol. 2015 Mar;10(3):500-8. (PMID: 25402569)

0 (B7-H1 Antigen)
0 (Biomarkers, Tumor)
0 (CD274 protein, human)

Thymic epithelial tumor

Date Created: 20180601 Date Completed: 20181005 Latest Revision: 20221207

20221213

PMC5937579

10.1155/2018/5830547

29850538